Physician profile
Daniel Kim
NPI 1528109121
$246.28
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $13.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $101.10 | 2019 | |
| Novo Nordisk INC | $28.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.61 | 2019 | |
| Valeritas, INC. | $18.54 | 2019 | |
| Glaxosmithkline, LLC. | $18.25 | 2019 | |
| Mannkind Corporation | $15.93 | 2019 | |
| Medtronic Minimed, INC. | $15.85 | 2019 | |
| Merck Sharp & Dohme LLC | $14.54 | 2019 | |
| Allergan, INC. | $13.66 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.